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ABSTRACT 
Antiviral drugs have significant action against influenza viruses A and B. Virus spread deadly disease in which many people die, and the country 
economy greatly suffer. Presently, most of the people need to get vaccination, which is depending on the dose limit in humans. It reacts directly or 
sometimes indirectly in the form of metabolites. However, it is mandatory to know how much drug is absorbed or metabolites concentration after 
administered. Therefore, pharmacokinetics data is very crucial for all drugs. Our review discusses the mechanism of drugs action and their activity 
and also describes how antiviral drugs and their metabolites are determined using highly sensitive instruments such as high-performance liquid 
chromatography (HPLC), ultra-pressure liquid chromatography (UPLC), and mass spectrometry (MS). Therefore, the present review gives brief 
information about antiviral drugs, their activity, biotransformation and analytical methods for quantification and this information will be helpful for 
any future studies done by experts in this field and will be beneficial for research scientists and influenza experts of all over the globe.  
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Respiratory system is commonly infected with influenza viruses [1] 
and mainly orthomyxoviridae family (A, B, C). Worldwide, 2.5–5 
hundred thousand people were reported death and 3-5 million 
diagnosed with acute illness [2] annually. Viruses classified with 
respect to activity of glycoproteins neuraminidase (N/NA), 
hemagglutinin (H/HA) and M2 ion channel. Influenza A and B are 
seasonal influenza with different subtypes such as H1–H16 (16 
hemagglutinin) and N1–N9 (9 neuraminidase). Well-known viruses 
H1N1 and H3N2 are generally subtyped of seasonal virus (Influenza 
A). The avian influenza virus H5N1 [3–5] have great interest among 
the people but swine influenza (novel H1N1) is completely different 
from seasonal H1N1 influenza virus [6]. In the 20th century, 20–50 
million people from different countries were killed with Spanish flu, 
1–2 million from Asian flu, and 7 hundred thousand from Hong Kong 
flu [7, 8]. Virus infection was initiated by hemagglutinin after 
binding with a receptor called Sialic acid, 1 (fig. 1). Then other cells 
infected by new viruses with the help of neuraminidase [9, 10]. Life 
threat influenza can only be overcome with annual immunization. 
However, the limitation related to efficacy, timeline and design of 
the vaccine production increase the need for antiviral drugs. The 
approved antiviral drugs M2 ion channel and NA inhibitors are the 
basic option for therapeutic treatment with prevention. This 
classification based on resistance behavior, tolerance study, 
pharmacokinetics and drugs mechanism of action [11–17].  
Neuraminidase inhibitors 
Proteins (H and N) are available on the walls of influenza virus 
surfaces. New viral molecule was released by host cell due to 
enzymatic function of neuraminidase, will help to catalyzed 
glycoside hydrolysis. As a result, α-ketosidically connected sialic acid 
with glycolipid, glycoprotein, and hemagglutinin divided increased 
infectious molecule. However, the nascent virus is still securing with 
host cell due to an interaction between HA/HA receptor. The viral 
molecule exhibit HA/HA receptors on the surface, which enables 
new molecules stick together. The viral particles emerged from the 
clump and host cell when neuraminidase receptor removed sialic 
acid. In the respiratory, glycosylated components are digested by 
neuraminidase, contribute viral infection. Therefore, design-based 
modern drug act on the site of neuraminidase inhibitors, depend on 
its clinical efficacy, mechanism, genetic role are the key feature for 
success [18–20]. The neuraminidase inhibitors prompt action and 
excellent mortality is the main reason for its demand [21, 22]. The 
drugs and their pharmaceutical formulations worked for the 
treatment of deadly disease are Oseltamivir 2, Laninamivir 3, 
Zanamivir 4, Peramivir 5 [23–25] (fig. 1), established on sialic acid 
transformation [26–28]. Influenza experts from different countries 
set up a neuraminidase inhibitors susceptibility network (NISN) for 
the outcome of clinical result and monitoring development process. 
This committee is participating to monitor liability studies for 
encouraging the people to know the exact method of evaluation and 
investigation process to control influenza virus. 
 
 
Fig. 1: Chemical structures of Sialic acid 1, Oseltamivir 2, 
Laninamivir 3, Zanamivir 4, and Peramivir 5 
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M2 ion channel inhibitors 
Amantadine 6 and Rimantadine 7 (fig. 2) licensed by United States of 
America (USA) in the years 1966 and 1993 respectively for the 
treatment of influenza A as M2 ion inhibitor. Allosteric inhibition 
controls the movement and activity of M2 by the presence of methyl 
group in amantadine; consequently, it blocks the release of RNA. It 
was found that M2 ion is successful for influenza A but ineffective 
towards influenza B. Therefore, these drugs are precise only for 
influenza A. M2 inhibitor has extraordinary response to antibiotic 
resistance [29, 30], but it is very less compared to neuraminidase 
inhibitors [31, 32]. Through endocytosis process, host cell allows 
viruses to enter. At low pH, M2 channel permits the virus to viral 
interior due to an activity of endosome responsible for maturation 
and growth of molecule. The reproduction is continued in cytoplasm, 
viral ribonucleic acid (RNA) and genetic material released from 
protein matrix [33]. Therefore, it is very important to develop 
inhibitors functioning against the virus but in native condition.  
 
 




Oseltamivir phosphate 8 is significant ester prodrug, applied orally 
for prevention and curing of influenza disease (A and B). It's brand 
name Tamiflu is available in quantity of 75 mg. The approved 
regimen for adults is 75 mg daily two times for 5 d with respect to 
influenza (A and B), but it is different for the prophylactic regimen. 
For control and prevention, daily dose is 75 mg once; for a minimum 
of 10 d up to 42 d. The intake dose for healthy participants follows 
linear pharmacokinetics in the range of 75–675 mg [34–36]. 
Oseltamivir is absorbed in the gastrointestinal tract then 
metabolized and converted into Oseltamivir carboxylate 9 (fig. 3) in 
the liver and later on, uniformly distributed in the body. After oral 
administration, therapeutic action continues for 30 min with the 
metabolite (80%) but the remaining 20% available 3–4 h. in plasma. 
The drug half-life is 1.8h. It was found that renal disease may affect 
active metabolite clearance and found that cytochrome P450 has 
only 3% interaction with plasma protein. Similar action occurs 
during glucuronosyl transferases [37–38]. 
 
 
Fig. 3: Chemical structures of Oseltamivir phosphate 8 (prodrug) 
and Oseltamivir carboxylate 9 (active metabolite) 
 
Zanamivir 
Relenza is the trade name of Zanamivir, an anti-influenza inhibitor, 
which obtained the regulatory approval in 1999. It targets 
respiratory site and available as inhaled powder. The 
pharmaceutical formulation has high potential against people 
diagnosed with deadly disease influenza A (H5N1). The maximum 
amount of 20 mg (10 mg twice) is allowed daily as inhalation, 
continued for 5 consecutive days. However, for prophylaxis, time 
and quantity limit is 10 mg daily for 28 d for children age five or 
more, and same for adults [39–40]. The nasal spray set down into 
posterior nasal and nostril approximately 88% but 13% in lung, 
78% in oropharynx deposited active site for replication of influenza 
virus [41]. Settle down in stomach (17%) and lung (2%) dose intake 
orally after fifty minutes [42]. Sputum and nasal wash sample 
resulted concentration about 50% inhibitory after 24 and 12 h. 
respectively [43] for healthy volunteers with 10 mg daily dose but 
20 mg amount with infected sample quantified after 4 d [44]. The 
unchanged drug (90%) was found with excreted urine sample 
recommended without biotransformation [41]. Therefore, the drug 
not metabolized in the liver.  
Peramivir 
Peramivir is a predominant cyclopentane based neuraminidase 
inhibitor. The binding capacity of the inhibitor will be half (IC50) 
with a concentration in the range 0.09–1.39 nM and 0.6–10.8 nM 
respectively for influenza A and B strains. This value is for 
Oseltamivir carboxylate 0.01–2.24 nM, 6.39–24.3 nM and for 
Zanamivir 0.30–2.32 nM, 1.53–17.0 nM [45]. The drug is productive 
without any complication for seasonal influenza viruses [46]. The 
Peramivir IV was first launched with trade name Rapiacta in Japan 
(2010). The drug prescribed for acute treatment in adults is 300 mg 
daily but for severe cases, hospitalized patients, 600 mg daily dose is 
recommended. The drug eliminated through renal and not 
metabolized in the human liver. 
Laninamivir 
The function of Laninamivir 3 is similar to Zanamivir, potent 
neuraminidase inhibitor for influenza viruses (A and B) [47–48]. 
Laninamivir octanoate is an inactive prodrug and the commercially 
approved product (inavir) is available in Japan since 2010 [49]. 
Single dose of Laninamivir octanoate hydrate is limited to children 
with age above 10 y is 40 mg and below 10 y is 20 mg. Laninamivir, 
active metabolite of Laninamivir octanoate (LO) formed within 24 h 
due to hydrolysis in the octanoyl ester site. When LO is mixed with 
water in the human body, equilibrated to form 3-acyl form 10, 2-acyl 
form 11 (fig. 4) known as major and minor metabolites [50]. 
 
 
Fig. 4: Chemical structures of Laninamivir octanoate 3-acyl form 
10 and 2-acyl form 11 
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Amantadine 6 is a very important drug as M2 proton channel 
inhibitor for influenza A. Symmetrel is the brand name normally 
used for amantadine. Its rate of absorption is high for young people 
compared to elder independents. Renal insufficiency does not 
appear to affect absorption, nor does the formulation used. First 
relative bioavailability studies of the oral administration reported 
that 86% recovery of the original dose (2–4 mg/kg) within 96 h 
from urine samples of five healthy men [51]. In case of ingestion 
after 72 h, 105 mg (52.5%) of the original dose was found in old man 
(84 y) urine [52]. Eight metabolites originated during metabolism. 
Besides the major metabolite produced by N-acetylation which is N–
acetylamantadine 12; other metabolites were observed. These are 
N–methylamantadine 13, N–dimethylamantadine 14, N–
methyleneamantadine 15, N–formylamantadine 16, and metabolites 
17, 18 and 19 (fig. 5) [53].  
 
 




Pharmaceutical formulation of Rimantadine is known as flumadine. 
Recommended daily dose for adults is 200 mg for 11–42 d, for 
children of 1–9 y (5 mg/kg) 150 mg is the maximum limit. Several 
studies concluded that 10% of the amantadine dose and 75% of the 
Rimantadine dose are metabolized in the liver [54–57]. The 
metabolites are determined as free Rimantadine 7, m–
hydroxyrimantadine 20, p–hydroxyrimantadine (equatorial 21 and 
axial 22) (fig. 6) [58–62]. 
 
 
Fig. 6: Chemical structures of m-hydroxyrimantadine (20) and 





UV–visible spectrophotometer is a simple and common technique 
for quantification of pure, pharmaceutical formulations and 
biological fluids. First order derivative spectrophotometry applied 
for Oseltamivir capsules having sophisticated additional software 
for pharmaceutical industry [63]. The drug (λmax=217, 208.5 nm) is 
stable and suitable with different stress condition in dosage form 
[64, 65]. Potassium permanganate as oxidizing agent in alkaline 
medium, no interference from excipients for capsules [66]. The pure 
drug with formulation is determined by monitoring reaction 
mechanism in buffer medium with 4-chloro-7-nitrobenzo-2-oxa-1, 
3-diazole [67]. Zanamivir is evaluated in tablet formulation at 260 nm, 
validated respect to an international conference on harmonization 
guidelines [68, 69]. Amantadine derivative and ion pair complex was 
developed with 1, 2-naphtoquinone-4-sulfonate, bromocressol green 
(BCG), bromophenol blue (BPB), bromothymol blue (BTB) and methyl 
orange in pharmaceutical preparation and plasma samples [70–73]. 
Rimantadine can also be determined spectrophotometrically using 1, 
2-naphtoquinone-4-sulfonic acid sodium salt as derivatizing reagent in 
pharmaceutical dosage form [74]. 
High-performance liquid chromatography 
High-performance liquid chromatography (HPLC) is an accurate 
instrument for pharmaceutical analysis. The inhibitor demand is 
increasing with time in the world because influenza viruses causes 
significant health alert. All determined drugs either applying 
ultraviolet detector or fluorescence detector. As well as used C18 
and C8 column with a different manufacturer. The single mobile 
phase is usually a combination of two or more solvents. The ratio 
of the mobile phase is changed with time; gradient method 
investigation resulted in drugs with a short time. During the 
analysis buffer also added for the preparation of the mobile phase. 
Therefore, for the quantification of neuraminidase and M2 ion 
channel inhibitor, numerous HPLC methods are developed based 
on the mobile phase composition and the stationary phase for 
pure bulk drug, tablet dosage form and biological fluids (table 1) 
[75–102]. 
High-performance thin layer chromatography 
Currently, the high-performance thin layer chromatography 
(HPTLC) has high demand because it involves fewer samples clean-
up, high throughput value, low-cost methodology. The fundamental 
advantage of HPTLC leads to compute several samples at one time. 
Oseltamivir study performed on silica gel 60F-254 coated aluminum 
plate consists of mobile phase (toluene: methanol: 
ammonia=3.5:1.5:0.2, v/v/v), detected at Rf value (0.45±0.02) for 
bulk and its dosage form [103]. This technique applied to evaluate 
Zanamivir in a pharmaceutical formulation having a correlation 
coefficient close to one [90, 104]. 
Capillary zone electrophoresis 
Capillary zone electrophoresis (CZE) is strong enough to large 
molecules additionally for small (organic/inorganic), separation 
technique controlled by electric field inside narrow bore 
capillaries. The method has several benefits with respect to fewer 
amounts of solvent, analyte and high resolution, applicable to 
forensic, environmental, clinical and pharmaceutical industry. It is 
a specific technique for the separation of the molecule along with 
enantiomers. The generic version of Oseltamivir was separated on 
fused capillary under potential (−15 kV) at room temperature. The 
analysis time is 1.5 min and detected at 226 nm included 
phosphate buffer [105]. Unmodified silica capillary, 4-
methylbenzylamine in ethanol (20%) as background electrolyte, 
maintained+20 V for separation at 210 nm within 3 min in 
Rimantadine tablets [106]. Pharmaceutical products can be 
estimated with derivatization agent 1, 2-naphthoquinone-4-
sulfonic acid by CZE in alkaline medium [107]. 
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Table 1: Important parameters for the determination of drugs using HPLC 






Oseltamivir Acetonitrile: Methanol = 50:30, v/v Purosphere C18 
(250×4.6 mm, 5μm) 
1.0 227 API [75] 
Potassium dihydrogen 
orthophosphate (pH 3.2): 
Acetonitrile: Methanol = 60:20:20, 
v/v/v 
YMC Pro C8 
(150×4.6 mm, 5μm) 
1.5 207 Capsules [76] 
Triethylamine (0.1%): Methanol = 
60: 40, pH 10.04 with Conc HCl  
Water’s X Bridge C18 
(250×4.6 mm, 5μm) 




Phosphate buffer (0.02 M, pH 5 with 
0.02 M TEA): Methanol = 50:50, v/v 
Purosphere Star 
RP–18e (150×4.6 
mm, 5 μm) 
1.5 215 Bulk drug and capsules [78] 
Mobile phase A–KH2PO4 buffer (0.05 
m, pH 6): Acetonitrile = 90:10, v/v 
Mobile phase B–KH2PO4 buffer (0.05 
m, pH 6): Acetonitrile = 10:90, v/v 
Gradient Programme 
ODS (50×4.6 mm, 
5μm) 
1.5 220 Bulk drug [79] 
Ammonium acetate buffer (pH 6.9): 
Acetonitrile = 60:40, v/v 
Purosphere C18 
(250×4.6 mm, 5μm) 
1.0 220 Bulk drug and dosage [80] 
Sodium acetate buffer (pH 4.5): 
Acetonitrile = 55:45, v/v 
Phenomenex Luna 
C18 (250×5 mm, 5 
mm) 
1.5 231 Bulk and dosage form [81] 
Acetonitrile: Nitric acid (10 mmol, 
pH 3) = 60:40, v/v 
Phenomenex C18 
(250x4.6 mm, 5 μm) 
1.0 λex 470 
λem 541 




orthophosphate (pH 3.5 with OPA): 
Acetonitrile = 50:50, v/v 
Princeton Spher C18 
(250x4.6 mm, 5 μm) 
1.0 254 Pharmaceutical dosage 
form 
[83] 
Bicarbonate buffer (0.05 M, pH 10): 
Acetonitrile = 70: 30, v/v 
X-Terra RP18 
(4.6×150 mm) 
1.0 220 Pharmaceutical product [84] 
Mobile phase A: Triethylamine 
(0.2%, pH 3 with OPA) buffer 
Mobile phase B: Acetonitrile 
Gradient programme 
Kromasil C18 
(250×4.6 mm, 5 µm) 
1.0 215 Quality control sample [85] 
Potassium dihydrogen 
orthophosphate (0.05 mmol, pH 3 
with OPA): Methanol: Acetonitrile = 
60:25:15, v/v/v 
Oyster RP18e 
(250×4.6 mm, 5 µm) 
1.0 207 Bulk and dosage form [86] 
Phosphate buffer (0.05 M, pH 3) 
with triethylamine (1 ml/l): 
Acetonitrile = 70:30, v/v 
Shimpack ODS 
(150×4.6 mm, 5 µm) 
1.6 215 Human serum [87] 
Formic acid (0.04 M, pH 3 with 
NaOH): Methanol = 50:50, v/v 
Zorbax CN (150×4.6 
mm, 5 µm) 
1.2 226 Capsule [88] 
Zanamivir 
 
Methanol: Water = 95:5, v/v Sunfire C18 (4.6×250 
mm, 5μm) 
1.0 285 Tablet dosage form [89] 
Phosphate buffer (0.02 M, pH 5): 
Methanol = 50:50, v/v 
Agilent zorbax 
eclipse C18 (150× 4.6 
mm, 5 μm) 
1.0 230 Bulk and capsule [90] 
Potassium dihydrogen 
orthophosphate (pH 4): Acetonitrile 
= 40:60, v/v 
Xterra Symmetry C8 
(4.6×150 mm, 3.5 
µm) 
0.5 230 Tablets [91] 
Ultrapure water: Acetonitrile = 98:2, 
v/v 
BDS Hypersil Cyano 
(250×4.6 mm; 5 
μm) 
0.5 230 Bulk drug [92] 
Acetonitrile: Water = 50:50, v/v Supelcocil C18 
(150×4.6 mm, 5 µm) 




Amantadine Mobile phase A: Acetonitrile (5%) in 
water 
Mobile phase B: Acetonitrile 
Gradient programme 
Hypersil C18 
(150×4.6 mm, 5 µm) 
1.0 λex 262 
λem 430 
Rat plasma [94] 
Ammonium acetate buffer (0.02 M): 
Methanol = 12:88, v/v 
Inertsil ODS-3V 
(250×4.6 mm, 5 μm) 
1.5 226 Bulk and formulation [95] 
Water: Acetonitrile = 40:60, v/v Phenomenex RP C18 
(250×4.6 mm, 5 
mm) 
1.0 273 Bulk and dosage form [96] 
Acetonitrile: Sodium acetate buffer 
(10 mmol, pH 3.5 with acetic acid): 
Methanol = 20:70:10, v/v/v 
Nucleosil CN (250x 
4.6 mm, 5 μm) 
1.5 λex 293. 
λem 382 
Human plasma [97] 
Mobile phase A: 0.1% 
trimethylamine solution (pH 3) 
Diamonsil C18 (200x 
4.6 mm, 5 μm) 
1.0 210, 280 Quality control granules [98] 
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Mobile phase B: Acetonitrile 
Gradient programme 
Water: Methanol = 15:85, v/v Lichrospher C18 
(150×6 mm, 5 µm) 
1.0 256 Rat plasma [99] 
Methanol: Acetic acid (pH 7) with 
water = 4:1, v/v 
Kanto C18 (150×4.6 
mm, 5 µm) 
0.8 λex 342 
λem 410 
Rat plasma [100] 
Rimantadine Ethylnitrile and octane sulfonic acid 
buffer (0.005 M, pH 6.7) = 60:40, v/v 
C18 (250× 4.6 mm) 1.0 259 Medicinal form [101] 
CH3OH: phosphate buffer, 25 
mmol/l (pH 3) = 50:50, v/v 
Monolithic RP 
(100×4.6 mm) 
0.5 λex 340 
λem 455 
Human urine [102] 
Methanol: Acetic acid (pH 7) with 
water = 4:1, v/v 
Kanto C18 (150×4.6 
mm, 5 µm) 
0.8 λex 342 
λem 410 
Rat plasma [100] 
 
Ultra pressure liquid chromatography 
Ultra pressure liquid chromatography (UPLC) is obligatory in 
respect to the analysis time; resolution enhanced its reliability in the 
pharmaceutical industry. The achieved data from developed 
methods are robust and accurate. The common available columns 
for UPLC are acquity BEH C8, acquity BEH C18, acquity BEH RP18 and 
acquity BEH phenyl. UV–Visible detector is commonly used detector 
for UPLC analysis. The method for Oseltamivir and its degraded 
product is established within 5 minute using mobile phase 
composition phosphate buffer, pH 3.5 and methanol (80: 20, v/v), 
detected at 207 nm [108]. 
Liquid chromatography-mass spectrophotometry 
Liquid chromatography-mass spectrophotometry technique is 
involved in the physical separation of compounds by liquid 
chromatography (LC) combined mass spectrometry (MS) for mass 
analysis [109–113]. Liquid chromatography can be high pressure or 
ultra-pressure. The structure of molecule elucidate after confirming 
the chemical composition of charged particles with respect to mass-
to-charge ratio. The molecule ionized by MS to produce fragments 
and its mass-to-charge ratio measured. This technique maintains 
high sensitivity compared to traditional techniques and selective to 
many applications. It has an excellent impact in the bioanalysis field 
mainly confronted to pharmacokinetics investigation of 
pharmaceuticals. Generally, LC installed octadecyl (C18) silica column 
but nowadays hydrophilic interaction based liquid chromatography 
(HILIC) has received more attention and recommended due to its 
potential to retain highly polar molecule with hydrophilic nature, 
but it needs to apply buffer as the mobile phase to minimize analyte 
and stationary phase ionic interaction. The LCMS method that was 
reported for inhibitors is presented in table 2 [114–137]. 
 
Table 2: LCMS method for neuraminidase and M2 ion channel inhibitors 





Ammonium formate (10 mmol, 
pH 3): Acetonitrile=20:80, v/v 
Synergi C18 (150×4.6 
mm, 4 µm) 
Amantadine 0.8 2.5 Human plasma [114] 
Mobile phase A: Ammonium 
formate (5 mmol, in water) 
Mobile phase B: Acetonitrile; 
Gradient programme 
Eclipse Plus C18 
(50x3 mm, 3.5 μm) 
Amantadine --- 5.3 Human plasma [115] 
Mobile phase A: Ammonium 
formate (10 mmol/l, 0.1% 
formic acid) 
Mobile phase B: Acetonitrile; 
Gradient programme 
Kinetex XB C18 (2.1× 
100 mm, 2.6 µm) 
Amantadine, 
Rimantadine 
0.3 15 Chicken tissue and 
eggs 
[116] 
Mobile phase A: Formic acid 
(0.1%) in water 
Mobile phase B: Acetonitrile; 
Gradient programme  
Eclipse Plus C18 
(100x2.1 mm, 1.8 
μm) Zorbax SB C18 




0.35 5 Chicken jerky [117] 
Mobile phase A: Formic acid 
(0.1%) in water 
Mobile phase B: Formic acid 
(0.1%) in acetonitrile; Gradient 
programme 
ZIC-HILIC (50×2.1 
mm, 5 µm) 
Zanamivir 0.4 15 Milli-Q water, 
sewage effluent, 
influent and surface 
water 
[118] 
Acetonitrile: 0.1% Formic acid = 
90:10, v/v 
Hydrosphere C18 




0.5 5.5 Human plasma 
 
[119] 
Mobile phase A: Formic acid 
(0.1%) in water 
Mobile phase B: Methanol; 
Gradient programme  
XDB C18 (2.1×150 
mm, 3.5 µm) 
Amantadine, 
Rimantadine 
0.3 10 Chicken, pig, pork, 
duck (liver, kidney, 
egg)  
[120] 
Mobile phase A–Methanol: 
Water=1:99, v/v 
Mobile phase B–Methanol: 
Water=99:1, v/v 
Gradient programme 
Eclipse Plus C18 




--- 4.5 Human plasma [121] 
Ammonium formate (10 mmol): 
Acetonitrile=30:70, v/v 
Symmetry C18 




1.0 2 Human plasma [122] 
Ammonium acetate (10 mmol, ZIC-HILIC (150x2.1 Oseltamivir and 0.3 10 Rat Plasma [123] 
Elzagheid et al. 
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pH 6): Acetonitrile=17:83, v/v mm, 3.5 µm) oseltamivir 
carboxylic acid 
Mobile phase A: Formic acid (50 
mmol) in water 
Mobile phase B: Formic acid (50 
mmol) in acetonitrile; Gradient 
programme  
Symmetry C18 
(3×150 mm, 5 μm) 
Hypercarb (3×100 







0.4 20 Poultry muscle [124] 
Mobile phase A: Formic acid 
(0.1%) Mobile phase B: 
Methanol; Gradient programme  
Synergi C18 (150×2.0 




0.25 9 Human plasma [125] 
Mobile phase A: Ammonium 
acetate (10 mmol, 1% acetic 




mm, 5 µm) 
Zanamivir 0.5 4 Human plasma [126] 
Ammonium acetate (10 mmol, 
pH 3.5): Formic acid (0.1%) in 
acetonitrile=20:80, v/v 
Chromatopack C18 




0.6 1 Human plasma [127] 
Mobile phase A: Ammonium 
acetate (10 mmol, 1% 




mm, 3 µm) 
Zanamivir  0.3 5 Rat and monkey 
plasma 
[128] 
Water: Acetonitrile = 60: 40 v/v, 
with 5 g/l formic acid 
Phenomenex Luna 
C8 (100×2 mm, 3 
µm) 
Amantadine 0.2 3 Human serum [129] 
Mobile phase A: Formic acid 
(0.1%) in water 
Mobile phase B: Methanol; 
Gradient programme  
XDB C18 (2.1× 150 
mm, 3.5 μm) 
Amantadine, 
Rimantadine 
0.3 10 Feed pigs and 
chicken 
[130] 
Mobile phase A: Formic acid 
(0.1% solution)  
Mobile phase B: Methanol; 
Gradient programme  
Agilent SB-Aq (3× 






0.3 11 Chicken muscle 
tissues 
[131] 
Mobile phase A: Formic acid 
(0.1%) in water 
Mobile phase B: Acetonitrile; 
Gradient programme  
BEH C18 (2.1× 100 







0.35 8 River waters, 
sewage effluent 
[132] 
Mobile phase A: Formic acid 
(0.1% solution)  
Mobile phase B: Acetonitrile; 
Gradient programme  
Acquity HSS T3 




0.7 8.5 Waste and surface 
water 
[133] 
Mobile phase A: Ammonium 
acetate (10 mmol), 5% 
acetonitrile adjusted pH 5 with 
acetic acid Mobile phase B: 
Ammonium acetate (10 mmol), 
pH 5 with acetic acid; Gradient 
programme  
Acquity HILIC 







0.7 8.5 River water [134] 
Mobile phase A: Formic acid 
(0.1% solution)  
Mobile phase B: Acetonitrile; 
Gradient programme  
Acquity HSS T3 




0.25 12 Chicken muscle [135] 
Mobile phase A: Formic acid 
(0.1%) in water 
Mobile phase B: Methanol; 
Gradient programme  
BEH C18 (2.1×100 
mm, 1.7 µm) 
Amantadine, 
Rimantadine 
0.3 10 Chicken muscle [136] 
Mobile phase A: Formic acid 
(0.1%) in water 
Mobile phase B: Formic acid 








0.35 6 Human plasma [137] 
 
The LCMS/MS investigation revealed that low concentration of 
amantadine present in plasma sample, does not require any 
derivatization during solid phase extraction, the developed method 
reported successfully bioequivalence study of healthy volunteers 
[114]. Amantadine–d15 internal standard can be used based on 
protein precipitation [115]. QuEChERS extraction method applied 
for chicken muscle, egg, pet treat sample [116, 117]. Zanamivir 
found in effluent sample and water from river in Japan [118]. The 
antiviral drugs and metabolite quantified applied flow rate (0.2–1 
ml/min) having run time between 1–20 minute with biological fluids 
and water sample [119–129]. Ultra pressure liquid chromatography 
combined with the mass spectrophotometer (triple quadrupole ion 
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trap) reported in feed sample illegal addition of amantadine and 
rimantadine [130]. Fourteen antiviral drugs detected within short 
time of 11 minute, multiple reaction monitoring ensured method 
specificity [131]. After winter season the inhibitors found in river 
water [132–134]. Amantadine and rimantadine are quantified in 
chicken muscle using different sorbent [135–136]. The UPLC method 
was first reported with whole blood sample, assay calculated using 
dried blood spot [137]. The minimum amount of sample required, 
elute from the column within 6 minute. The correlation coefficient of 
Oseltamivir and its active metabolites Oseltamivir carboxylate was 
greater than 0.99. Sample collection is very important parameter for 
this analysis. Therefore, the developed method validated successfully 
for human plasma of healthy volunteers.  
CONCLUSION 
Antiviral drugs are very useful versus influenza viruses and 
molecules that are actively participated for deadly diseases. The 
developed novel drugs are showing great potential for the 
prevention of influenza. It was evident that for controlling influenza, 
administered single dose drug to human and all animals including 
farm animals is required. All inhibitors can be applied during 
epidemic or seasonal conditions. Their main function, through 
vaccination, is to control the activity of viruses, reduce and manage 
pandemic viruses. All these mentioned drugs are also important for 
patients hospitalized due to influenza. Although the existing drugs 
are doing well, influenza experts are looking forward to identify 
other new drugs that exert antiviral activity like the approved ones 
and can be applicable as future antiviral agents for influenza viruses. 
Therefore, the present review gives brief information about antiviral 
drugs, their activity, biotransformation and analytical methods for 
quantification and this information will be helpful for any future 
studies done by experts in this field. 
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